Sutro Biopharma, Inc. announced the strengthening of key leadership roles including the promotion of Robert Kiss, Ph.D., to Senior Vice President, Process and Analytical Development, and the appointment of Ana Oaknin Benzaquen, M.D., Ph.D., to company's Clinical Advisory Board. As part of this promotion, Dr. Kiss is wholly responsible for the end-to-end industrialization of company's proprietary and integrated cell-free protein synthesis platform, XpressCF®, encompassing process scalability, technology transfers to CMO's, and CMC strategies to ensure successful global regulatory filings. Dr. Kiss joined the company in 2017 as Vice President of Process and Analytical Development, after working at Genentech for nearly 24 years, where his last role was of Distinguished Engineer and Senior Director of Late-Stage Cell Culture process development. Dr. Oaknin is the Head of the Gynecological Tumor Unit and full-time Senior Attending Physician at Medical Oncology Department at the Vall d'Hebron University Hospital in Barcelona, as well as the Principal Clinical Investigator of the Gynecological Malignancies Group at the Vall d'Hebrón Institute of Oncology.